BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Reactive Oxygen Species Go Beyond Photodynamic Therapy
DTSTART:20190618T160000
DTEND:20190618T170000
DTSTAMP:20260921T173506Z
UID:8a3c56fb589d523a3c203aede3f8757295b7a95371f4ef37499a4825
CATEGORIES:Conferences - Seminars
DESCRIPTION:Xiaoyuan (Shawn) Chen\, Ph.D.\, National Institute of Biomedic
 al Imaging and Bioengineering (NIBIB)\, NIH\, Bethesda\, MD (USA)\nBIOENGI
 NEERING SEMINAR\n \nAbstract:\nThe reactive oxygen species (ROS)-mediated
  mechanism is the major cause underlying the efficacy of photodynamic ther
 apy (PDT). The PDT procedure is based on the cascade of synergistic effect
 s between light\, a photosensitizer (PS) and oxygen\, which greatly favors
  the spatiotemporal control of the treatment. This procedure has also evok
 ed several unresolved challenges at different levels including (i) the lim
 ited penetration depth of light\, which restricts traditional PDT to super
 ficial tumors\; (ii) oxygen reliance does not allow PDT treatment of hypox
 ic tumors\; (iii) light can complicate the phototherapeutic outcomes becau
 se of the concurrent heat generation\; (iv) specific delivery of PSs to su
 b-cellular organelles for exerting effective toxicity remains an issue\; a
 nd (v) side effects from undesirable white-light activation and self-catal
 yzation of traditional PSs. In this talk\, the current status and the poss
 ible opportunities of nanomedicine for ROS generation for cancer therapy w
 ill be discussed in detail.\n\nBio:\nDr. Xiaoyuan (Shawn) Chen received hi
 s PhD in Chemistry from the University of Idaho (1999). After two postdocs
  at Syracuse University and Washington University in St. Louis\, he starte
 d his Assistant Professorship in 2002 and then moved to Stanford in 2004. 
 He moved to NIH in 2009 and became a Senior Investigator and Chief of the 
 Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National I
 nstitute of Biomedical Imaging and Bioengineering (NIBIB)\, NIH. His curre
 nt research interests include development of molecular imaging toolbox for
  better understanding of biology\, early diagnosis of disease\, monitoring
  therapy response\, and guiding drug discovery/development. His lab puts s
 pecial emphasis on high-sensitivity nanosensors for biomarker detection an
 d theranostic nanomedicine for imaging\, gene and drug delivery\, and moni
 toring of treatment. Dr. Chen has published over 750 peer-reviewed papers 
 (H-index = 129\, total citations > 60\,000 based on Google Scholar) and nu
 merous books and book chapters. He is the founding editor of journal “Th
 eranostics” (2017 IF = 8.537). He was elected as AIMBE Fellow (2017)\, r
 eceived Michael J. Welch\, PhD Award (2019)\, ACS Bioconjugate Chemistry L
 ecturer Award (2016)\, NIH Director’s Award (2014) and NIBIB Mentor Awar
 d (2012). He has served in the past as the President of Chinese-American S
 ociety of Nanomedicine and Nanobiotechnology (CASNN) and President of the 
 Radiopharmaceutical Science Council (RPSC)\, Society of Nuclear Medicine a
 nd Molecular Imaging (SNMMI).\n\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR